Price
$33.51
Decreased by -8.79%
Dollar Volume
37.11 M
ADR%
5.8
Earnings Report Date (estimate)
Feb 6, 23 (0.44)
Market Cap.
3.81 B
Shares Float
102.73 M
Shares Outstanding
113.81 M
Beta
1.09
Price / Earnings
-31.17
BPR
146.76
20D Range
28.52 37.95
50D Range
27.75 41.03
200D Range
26.81 48.48
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 28, 22 -0.81
Decreased by -32.79%
-0.16
Decreased by -406.25%
Aug 4, 22 -0.68
Decreased by -134.48%
-0.51
Decreased by -33.33%
May 10, 22 0.41
Increased by +257.69%
-0.08
Increased by +612.50%
Feb 2, 22 -0.60
Decreased by -200.00%
-0.45
Decreased by -33.33%
Nov 22, 21 -0.61
Decreased by -27.08%
-0.10
Decreased by -510.00%
Aug 5, 21 -0.29
Decreased by -123.08%
-0.20
Decreased by -45.00%
May 4, 21 -0.26
Decreased by -30.00%
-0.13
Decreased by -100.00%
Feb 4, 21 -0.20
Decreased by -566.67%
0.12
Decreased by -266.67%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 31.57 M
Decreased by -17.52%
-85.51 M
Decreased by -34.93%
Decreased by -270.82%
Decreased by -63.60%
Jun 30, 22 32.41 M
Decreased by -29.37%
-72.05 M
Decreased by -140.76%
Decreased by -222.28%
Decreased by -240.89%
Mar 31, 22 151.81 M
Increased by +362.66%
44.37 M
Increased by +265.43%
Increased by +29.23%
Increased by +135.76%
Dec 31, 21 27.44 M
Increased by +28.80%
-62.87 M
Decreased by -203.26%
Decreased by -229.13%
Decreased by -135.44%
Sep 30, 21 38.28 M
Increased by +401.56%
-63.37 M
Decreased by -30.85%
Decreased by -165.54%
Increased by +73.91%
Jun 30, 21 45.89 M
Increased by +67.63%
-29.92 M
Decreased by -119.85%
Decreased by -65.21%
Decreased by -31.15%
Mar 31, 21 32.81 M
Increased by +39.45%
-26.82 M
Decreased by -35.20%
Decreased by -81.73%
Increased by +3.05%
Dec 31, 20 21.30 M
Decreased by -27.68%
-20.73 M
Decreased by -675.40%
Decreased by -97.32%
Decreased by -972.10%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.